Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31.
about
Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing ControversiesPhase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeksImpact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials.Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancerTherapy-associated effects in the prostate gland.Combining radiation therapy and androgen deprivation for localized prostate cancer-a critical review.Radiation protection of the gastrointestinal tract and growth inhibition of prostate cancer xenografts by a single compound.Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): the example of SERM therapy monitoring as a unique tool to individualize therapy.Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer.An update on androgen deprivation therapy for prostate cancer.Role of hormonal therapy for prostate cancer: perspective from Japanese experiences.Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy.Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspectiveChallenges of guarantee-time biasNeoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study.The role of chemotherapy and new targeted agents in the management of primary prostate cancer.Radiation therapy and androgen deprivation in the management of high risk prostate cancer.Bone health management in prostate cancer patients receiving androgen deprivation therapy.Radiotherapy for high-risk prostate cancer.Synergistic action of image-guided radiotherapy and androgen deprivation therapy.The role of androgen deprivation therapy plus radiation therapy in patients with non-metastatic prostate cancer.Radical radiotherapy for high-risk prostate cancer in older menSalvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy.Quality of life of 1276 elderly patients with prostate cancer, starting treatment with a gonadotropin-releasing hormone agonist: results of a French observational study.Surrogate endpoints in early prostate cancer researchEfficacy characteristics of different therapeutic modalities for locally advanced prostate cancer: a Bayesian network meta-analysis of randomized controlled trials
P2860
Q26744606-DA3EFC45-D663-45BE-9A4A-8D178067D214Q33613649-E254DC93-DDC6-4560-8FFA-3422E587E69CQ33766974-970C46DD-69C0-403B-9D29-7F20FABA8628Q34104391-5C8F58C5-7FC3-4AB4-8609-BEB09C6E5529Q34115527-B6F23BB4-42E5-4D53-B752-F79C71C608D8Q34171941-00D9727D-0D9E-4AA2-9E11-12178D4D4258Q34646655-AA16DABC-F254-47EF-ACF2-EA5B7ADE00E8Q34779138-5ECACB90-28E7-45D4-A8BE-CBEB8A710962Q35433102-C3EE412E-C343-4F4D-9D6A-DB02A10951D3Q36289952-7568BBB4-BB99-4E21-9C5A-B23249234D0CQ36450795-EAE2A889-F4E6-4A2D-B11B-2F83C618042AQ36557840-22106D78-F24F-4CE3-B056-EA9449C1F70CQ36982057-82BEFD2A-D558-48C5-B2A4-125CED06C6AEQ37044229-625224FA-2F4A-443B-AD9C-829B2CCD3F03Q37066734-F6B34FBD-5DF8-4EA8-883F-11F69D5E88FFQ37523203-E633A70C-6C25-4B9E-B96A-D999C5E9842DQ37708171-E245A0EC-4CB0-4F06-9628-F1694256D8ADQ37873973-867229F8-ABFD-4CD2-9641-6A0271481251Q37909777-34489D1B-E5F9-4B7D-995D-855E3A4EDFFAQ38364578-F698546E-E44A-4407-BA3C-FC90030E2C72Q38387844-AE185A38-6462-4EDD-9BD6-CFF5176BA260Q38910225-D4F90B4C-4B38-4C54-B084-B848B57CCCD4Q41334584-06C14754-F7F4-4010-99E6-60157B76397AQ41864424-5CA72CBA-E35D-4088-B457-D3112A9D9EDBQ42256057-E6D682C4-ADD4-4708-838F-9451831E6C26Q48084722-E0F3C0DC-966C-4247-94F9-E0A55FFC9009Q57112339-7012F63D-5F89-4A35-85B1-3A06B6A57F21Q58127719-BCA9A60A-4804-4EBF-A755-94AAEBA189AD
P2860
Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Impact of the duration of adju ...... ondary analysis of RTOG 85-31.
@en
Impact of the duration of adju ...... ondary analysis of RTOG 85-31.
@nl
type
label
Impact of the duration of adju ...... ondary analysis of RTOG 85-31.
@en
Impact of the duration of adju ...... ondary analysis of RTOG 85-31.
@nl
prefLabel
Impact of the duration of adju ...... ondary analysis of RTOG 85-31.
@en
Impact of the duration of adju ...... ondary analysis of RTOG 85-31.
@nl
P2093
P2860
P356
P1476
Impact of the duration of adju ...... ondary analysis of RTOG 85-31.
@en
P2093
Howard Sandler
Kyounghwa Bae
Luis Souhami
Miljenko Pilepich
P2860
P304
P356
10.1200/JCO.2008.17.4052
P407
P577
2009-03-23T00:00:00Z